2019-11-04: New product launch- QDx Malaria Pv/Pf
The effort to eradicate malaria is based on comprehensive interventions, including strategies to diagnosis the disease. In malaria-endemic regions, many patients are presumptively treated for malaria on the basis of symptoms alone (fever), although malaria is not the only cause of fever . Presumptive treatment of fever with antimalarials is widely practiced to reduce malaria-attributable morbidity, and mortality, especially at the primary healthcares where microscopy is not available .
Overdiagnosis of malaria implies under-diagnosis and inappropriate treatment of non-malarial febrile illness while a high proportion of such illnesses are self-limiting diseases and other diseases. The extensive deployment of anti-malarial drugs has provided strong selective pressure on human malaria parasites to evolve mechanisms of resistance and the increased cost of treatments . World Health Organization (WHO) is trying to eliminate presumptive drug treatment of malaria and currently makes the tentative recommendation that parasite-based diagnosis should be used in all cases. All suspected malaria cases are confirmed with a parasite-based diagnostic test prior to therapy unless parasitologic diagnostic capabilities are not available.
Early and accurate diagnosis of malaria is needed in improving the effectiveness of malaria management.
DiaSys Diagnostics India Pvt. Ltd introduces “QDx Malaria Pf/Pv”- an antigen detection kit based on immunochromatographic assay for the qualitative detection and differentiation of P. falciparum from P. vivax in human whole blood as an aid in the diagnosis of malaria infection.
The kit has capability of detecting low parasitic count sample is reliable to meet WHO and laboratory requirement. Its provides ease of interpretation with two colour band which differentiates control and test band during the screening of malarial cases within 5-20 minutes.